The treatment, which GW Pharma hopes to market under the nameĀ Epidiolex [6], is produced in the U.K. from a plant that has been bred to have a high cannabidiol, or CBD, content, Chief Executive Officer Justin Gover said in an interview earlier this month. The chemical is purified and made into a strawberry-flavored oral solution, he said.
Links
[1] https://www.bloomberg.com/news/articles/2018-04-17/drug-made-from-cannabis-plant-gets-backing-from-fda-staff
[2] http://rethinkpot.org/tags/gw-pharm
[3] http://rethinkpot.org/tags/epidiolex
[4] http://rethinkpot.org/tags/seizure
[5] http://rethinkpot.org/tags/fda
[6] https://www.gwpharm.com/products-pipeline